Gemifloxacin Indications
Gemifloxacin is FDA-approved for two specific indications: community-acquired pneumonia (CAP) and acute bacterial exacerbation of chronic bronchitis (AECB). 1
FDA-Approved Indications
1. Community-Acquired Pneumonia (CAP)
Gemifloxacin 320 mg once daily for 5-7 days is approved for treating mild-to-moderate CAP caused by susceptible organisms, including:
- Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])
- Haemophilus influenzae
- Haemophilus parainfluenzae
- Moraxella catarrhalis
- Klebsiella pneumoniae (many strains only moderately susceptible)
- Chlamydia pneumoniae
- Mycoplasma pneumoniae 1
Notably, gemifloxacin is specifically approved for multi-drug resistant S. pneumoniae, which includes strains resistant to penicillin (MIC ≥2 μg/mL), second-generation cephalosporins, macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. 1
2. Acute Bacterial Exacerbation of Chronic Bronchitis (AECB)
Gemifloxacin 320 mg once daily for 5 days is approved for AECB caused by the same spectrum of pathogens listed above. 1
Key Microbiological Activity
The drug demonstrates exceptional potency against respiratory pathogens:
- S. pneumoniae: MIC₉₀ 0.03 μg/mL (most potent fluoroquinolone)
- H. influenzae: MIC₉₀ <0.06 μg/mL
- M. catarrhalis: MIC₉₀ 0.03 μg/mL 2, 3
Important Clinical Context
Gemifloxacin is NOT approved for pediatric use - pharmacokinetic data in children have not been established. 1 The guideline evidence confirms that while other respiratory fluoroquinolones like levofloxacin have been studied in children, gemifloxacin lacks pediatric approval. 4
Dosing Adjustments
- Renal impairment (CrCl ≤40 mL/min): Dose modification required 1
- Hepatic impairment: No dose adjustment needed, even in severe (Child-Pugh Class C) disease 1
Clinical Efficacy Data
Meta-analysis of 10 randomized controlled trials involving 3,940 patients demonstrated that gemifloxacin achieved superior treatment success compared to other antibiotics (OR 1.39,95% CI 1.15-1.68) for CAP and AECB, with clinical success rates of 93.9-95.9% for CAP and 96.1-97.5% for AECB. 5
Common Pitfall
Do not use gemifloxacin for methicillin-resistant Staphylococcus aureus (MRSA) infections - it has insufficient activity despite being labeled as active against methicillin-susceptible S. aureus. 6